Latest Mycobacterium vaccae Stories
Immunitor, Inc., a commercial stage company committed to developing oral therapeutic vaccines, today announced that its second Phase II trial of oral TB vaccine with heat-killed Mycobacterium
Immunitor company announces publication of a successful clinical trial in 43 patients with tuberculosis who were given daily pill of therapeutic vaccine containing heat-killed Mycobacterium vaccae.
Immune Network Ltd. (IMMFF), announces the completion of a Phase II trial of a once-daily M. vaccae pill (V7) conducted by Immunitor in Ukraine.
Exposure to specific bacteria in the environment, already believed to have antidepressant qualities, could increase learning behavior according to research presented today at the 110th General Meeting of the American Society for Microbiology in San Diego.